The medical treatment of Cushing’s syndrome.

Miller, JW
·
Crapo, L

Abstract: No abstract available

Publication Date: 1993-08-01 PubMed ID: 7693447DOI: 10.1210/edrv-14-4-443Google Scholar: Lookup

The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.

Facebook X LinkedIn Email

Cite This
Publication
Affiliations
MeSH
Citations

Journal Article
Review

Cite This Article

APA

Miller JW, Crapo L. (1993). The medical treatment of Cushing’s syndrome. Endocr Rev, 14(4), 443-458. https://doi.org/10.1210/edrv-14-4-443

Publication

Endocrine reviews

ISSN: 0163-769X

NlmUniqueID: 8006258

Country: United States

Language: English

Volume: 14

Issue: 4

Pages: 443-458

Researcher Affiliations

Miller, J W

Division of Endocrinology, Gerontology and Metabolism, Stanford University School of Medicine, California 94305.

Crapo, L

MeSH Terms

Adrenal Cortex Neoplasms / drug therapy
Adrenal Glands / surgery
Aminoglutethimide / adverse effects
Aminoglutethimide / therapeutic use
Animals
Bromocriptine / adverse effects
Bromocriptine / therapeutic use
Cushing Syndrome / drug therapy
Cushing Syndrome / radiotherapy
Cushing Syndrome / surgery
Cyproheptadine / adverse effects
Cyproheptadine / therapeutic use
Dogs
Horses
Humans
Ketoconazole / adverse effects
Ketoconazole / therapeutic use
Metyrapone / adverse effects
Metyrapone / therapeutic use
Mifepristone / therapeutic use
Mitotane / adverse effects
Mitotane / therapeutic use
Octreotide / therapeutic use
Palliative Care
Pituitary Gland / diagnostic imaging
Pituitary Gland / surgery
Radiography
Valproic Acid / adverse effects
Valproic Acid / therapeutic use

Citations

This article has been cited 41 times.

Sulu C, Gul N, Tanrikulu S, Ciftci S, Yener Ozturk F, Sarac B, Ersungur EB, Tanriover E, Sahin S, Ozkaya HM, Poyraz BC, Kadioglu P. Risk of impulse control disorders in patients with Cushing's disease: do not blame cabergoline but do not give up caution.. Pituitary 2023 Aug;26(4):495-509.
doi: 10.1007/s11102-023-01342-3pubmed: 37474846google scholar: lookup
Pivonello R, Pivonello C, Simeoli C, De Martino MC, Colao A. The dopaminergic control of Cushing's syndrome.. J Endocrinol Invest 2022 Jul;45(7):1297-1315.
doi: 10.1007/s40618-021-01661-xpubmed: 35460460google scholar: lookup
Sherry AD, Khattab MH, Xu MC, Kelly P, Anderson JL, Luo G, Utz AL, Chambless LB, Cmelak AJ, Attia A. Outcomes of stereotactic radiosurgery and hypofractionated stereotactic radiotherapy for refractory Cushing's disease.. Pituitary 2019 Dec;22(6):607-613.
doi: 10.1007/s11102-019-00992-6pubmed: 31552580google scholar: lookup
Yurekli BS, Karaca B, Kisim A, Bozkurt E, Atmaca H, Cetinkalp S, Ozgen G, Yilmaz C, Uzunoglu S, Uslu R, Saygili F. AT-101 acts as anti-proliferative and hormone suppressive agent in mouse pituitary corticotroph tumor cells.. J Endocrinol Invest 2018 Feb;41(2):233-240.
doi: 10.1007/s40618-017-0733-8pubmed: 28730425google scholar: lookup
Haraj NE, El Aziz S, Chadli A. [Cushing syndrome in adolescents: report of 18 patients].. Pan Afr Med J 2015;22:347.
doi: 10.11604/pamj.2015.22.347.8135pubmed: 26985265google scholar: lookup
Price LH, Malison RT, McDougle CJ, Pelton GH. Antiglucocorticoids as Treatments for Depression : Rationale for Use and Therapeutic Potential.. CNS Drugs 1996 May;5(5):311-20.
doi: 10.2165/00023210-199605050-00001pubmed: 26071044google scholar: lookup
Pivonello R, De Leo M, Cozzolino A, Colao A. The Treatment of Cushing's Disease.. Endocr Rev 2015 Aug;36(4):385-486.
doi: 10.1210/er.2013-1048pubmed: 26067718google scholar: lookup
Petersenn S, Fleseriu M. Pituitary-directed medical therapy in Cushing's disease.. Pituitary 2015 Apr;18(2):238-44.
doi: 10.1007/s11102-015-0639-4pubmed: 25627118google scholar: lookup
Fleseriu M, Petersenn S. Medical therapy for Cushing's disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers.. Pituitary 2015 Apr;18(2):245-52.
doi: 10.1007/s11102-014-0627-0pubmed: 25560275google scholar: lookup
Wang Y, Li J, Tohti M, Hu Y, Wang S, Li W, Lu Z, Ma C. The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy.. J Exp Clin Cancer Res 2014 Jul 16;33(1):56.
doi: 10.1186/s13046-014-0056-ypubmed: 25027022google scholar: lookup
Sakihara S, Kageyama K, Yamagata S, Terui K, Daimon M, Suda T. A case of ectopic ACTH syndrome treated with intermittent administration of dopamine agonists.. Endocrinol Diabetes Metab Case Rep 2014;2014:140001.
doi: 10.1530/EDM-14-0001pubmed: 24683487google scholar: lookup
Gu00fcven A, Baltacu0131ou011flu F, Dursun F, Cebeci AN, Ku0131rmu0131zu0131bekmez H. Remission with cabergoline in adolescent boys with Cushing's disease.. J Clin Res Pediatr Endocrinol 2013 Sep 10;5(3):194-8.
doi: 10.4274/Jcrpe.1007pubmed: 24072089google scholar: lookup
Sundaram NK, Carluccio A, Geer EB. Characterization of persistent and recurrent Cushing's disease.. Pituitary 2014 Aug;17(4):381-91.
doi: 10.1007/s11102-013-0511-3pubmed: 23990348google scholar: lookup
Carmichael JD, Fleseriu M. Mifepristone: is there a place in the treatment of Cushing's disease?. Endocrine 2013 Aug;44(1):20-32.
doi: 10.1007/s12020-012-9846-1pubmed: 23192246google scholar: lookup
Fleseriu M, Petersenn S. Medical management of Cushing's disease: what is the future?. Pituitary 2012 Sep;15(3):330-41.
doi: 10.1007/s11102-012-0397-5pubmed: 22674211google scholar: lookup
El-Zammar D, Akagami R. ICA Occlusion by an ACTH-secreting pituitary adenoma post-TSS and irradiation.. Mcgill J Med 2011 Jun;13(1):31.
pubmed: 22399870
Fassnacht M, Libu00e9 R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician's update.. Nat Rev Endocrinol 2011 Jun;7(6):323-35.
doi: 10.1038/nrendo.2010.235pubmed: 21386792google scholar: lookup
Biller BM, Colao A, Petersenn S, Bonert VS, Boscaro M. Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas.. BMC Endocr Disord 2010 May 17;10:10.
doi: 10.1186/1472-6823-10-10pubmed: 20478050google scholar: lookup
Vilar L, Naves LA, Azevedo MF, Arruda MJ, Arahata CM, Moura E Silva L, Agra R, Pontes L, Montenegro L, Albuquerque JL, Canadas V. Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease.. Pituitary 2010 Jun;13(2):123-9.
doi: 10.1007/s11102-009-0209-8pubmed: 19943118google scholar: lookup
Hadoke PW, Iqbal J, Walker BR. Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease.. Br J Pharmacol 2009 Mar;156(5):689-712.
doi: 10.1111/j.1476-5381.2008.00047.xpubmed: 19239478google scholar: lookup
Colao A, Pivonello R, Di Somma C, Savastano S, Grasso LF, Lombardi G. Medical therapy of pituitary adenomas: effects on tumor shrinkage.. Rev Endocr Metab Disord 2009 Jun;10(2):111-23.
doi: 10.1007/s11154-008-9107-zpubmed: 18791829google scholar: lookup
de Bruin C, Feelders RA, Lamberts SW, Hofland LJ. Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome.. Rev Endocr Metab Disord 2009 Jun;10(2):91-102.
doi: 10.1007/s11154-008-9082-4pubmed: 18642088google scholar: lookup
Labeur M, Paez-Pereda M, Arzt E, Stalla GK. Potential of retinoic acid derivatives for the treatment of corticotroph pituitary adenomas.. Rev Endocr Metab Disord 2009 Jun;10(2):103-9.
doi: 10.1007/s11154-008-9080-6pubmed: 18604646google scholar: lookup
Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.. J Clin Endocrinol Metab 2008 Jul;93(7):2454-62.
doi: 10.1210/jc.2007-2734pubmed: 18413427google scholar: lookup
Fazel P, Ganesa P, Mennel RG, Austin NA. The ectopic adrenocorticotropic hormone syndrome in carcinoid tumors.. Proc (Bayl Univ Med Cent) 2008 Apr;21(2):140-3.
doi: 10.1080/08998280.2008.11928380pubmed: 18382753google scholar: lookup
Shraga-Slutzky I, Shimon I, Weinshtein R. Clinical and biochemical stabilization of Nelson's syndrome with long-term low-dose cabergoline treatment.. Pituitary 2006;9(2):151-4.
doi: 10.1007/s11102-006-9290-4pubmed: 16845600google scholar: lookup
Ivu00e1n G, Szigeti-Csu00facs N, Olu00e1h M, Nagy GM, Gu00f3th MI. Treatment of pituitary tumors: dopamine agonists.. Endocrine 2005 Oct;28(1):101-10.
doi: 10.1385/endo:28:1:101pubmed: 16311416google scholar: lookup
Thanabalasingham G, Karavitaki N, Cudlip S, Wass JA. Treatment of pituitary tumors: history.. Endocrine 2005 Oct;28(1):3-8.
doi: 10.1385/ENDO:28:1:003pubmed: 16311405google scholar: lookup
van der Hoek J, Lamberts SW, Hofland LJ. The role of somatostatin analogs in Cushing's disease.. Pituitary 2004;7(4):257-64.
doi: 10.1007/s11102-005-1404-xpubmed: 16132202google scholar: lookup
Nieman LK. Medical therapy of Cushing's disease.. Pituitary 2002;5(2):77-82.
doi: 10.1023/a:1022308429992pubmed: 12675504google scholar: lookup
T'Sjoen G, Defeyter I, Van De Saffele J, Rubens R, Vandeweghe M. Macroprolactinoma associated with Cushing's disease, successfully treated with cabergoline.. J Endocrinol Invest 2002 Feb;25(2):172-5.
doi: 10.1007/BF03343983pubmed: 11929090google scholar: lookup
Aniszewski JP, Young WF Jr, Thompson GB, Grant CS, van Heerden JA. Cushing syndrome due to ectopic adrenocorticotropic hormone secretion.. World J Surg 2001 Jul;25(7):934-40.
doi: 10.1007/s00268-001-0032-5pubmed: 11572035google scholar: lookup
Sonino N, Fava GA, Fallo F, Franceschetto A, Belluardo P, Boscaro M. Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease.. Pituitary 2000 Oct;3(2):55-9.
doi: 10.1023/a:1009986822146pubmed: 11141696google scholar: lookup
Orrego JJ, Barkan AL. Pituitary disorders. Drug treatment options.. Drugs 2000 Jan;59(1):93-106.
doi: 10.2165/00003495-200059010-00006pubmed: 10718101google scholar: lookup
Pivonello R, Faggiano A, Di Salle F, Filippella M, Lombardi G, Colao A. Complete remission of Nelson's syndrome after 1-year treatment with cabergoline.. J Endocrinol Invest 1999 Dec;22(11):860-5.
doi: 10.1007/BF03343660pubmed: 10710275google scholar: lookup
Losa M, Barzaghi RL, Mortini P, Franzin A, Mangili F, Terreni MR, Giovanelli M. Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors : comparison between micro- and macroadenomas.. Am J Pathol 2000 Jan;156(1):245-51.
doi: 10.1016/S0002-9440(10)64725-6pubmed: 10623673google scholar: lookup
Finkenstedt G, Gasser RW, Hu00f6fle G, Lhotta K, Ku00f6lle D, Gschwendtner A, Janetschek G. Pheochromocytoma and sub-clinical Cushing's syndrome during pregnancy: diagnosis, medical pre-treatment and cure by laparoscopic unilateral adrenalectomy.. J Endocrinol Invest 1999 Jul-Aug;22(7):551-7.
doi: 10.1007/BF03343608pubmed: 10475154google scholar: lookup
Colao A, Pivonello R, Tripodi FS, Orio F Jr, Ferone D, Cerbone G, Di Somma C, Merola B, Lombardi G. Failure of long-term therapy with sodium valproate in Cushing's disease.. J Endocrinol Invest 1997 Jul-Aug;20(7):387-92.
doi: 10.1007/BF03347989pubmed: 9309536google scholar: lookup
Petrini L, Gasperi M, Pilosu R, Marcello A, Martino E. Long-term treatment of Nelson's syndrome by octreotide: a case report.. J Endocrinol Invest 1994 Feb;17(2):135-9.
doi: 10.1007/BF03347703pubmed: 8006335google scholar: lookup
Engelhardt D. Steroid biosynthesis inhibitors in Cushing's syndrome.. Clin Investig 1994 Jul;72(7):481-8.
doi: 10.1007/BF00207474pubmed: 7981573google scholar: lookup
Terzolo M, Alu00ec A, Pia A, Bollito E, Reimondo G, Paccotti P, Scardapane R, Angeli A. Cyclic Cushing's syndrome due to ectopic ACTH secretion by an adrenal pheochromocytoma.. J Endocrinol Invest 1994 Dec;17(11):869-74.
doi: 10.1007/BF03347794pubmed: 7745235google scholar: lookup